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Young patients with cervical cancer who undergo chemoradiation might be interested in fertility preservation, not
only dependent upon the use of a gestational carrier as maybe achieved by the use of ovarian transposition and
cryo-conservation of oocytes or ovarian tissue, but may prefer to carry pregnancy to term after cancer treatment.
The latter approach is a non-established concept needing both modern radiation therapy approaches as well as
modifications -if at all possible- in current recommendations for target volume delineation to spare dose to the
unaffected uterus. Future strategies to serve selected patients in this respect should only be conducted in
prospective clinical evaluations and are critically discussed in this article.
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Cervical cancer is one of the most common cancers diag-
nosed in female patients under the age of 40 years [1].
Successful treatment leading to cure is the major concern
for most patients. However, for young patients, preserva-
tion of fertility and pregnancy related complications after
treatment are also of importance. Therefore, if present,
the desire to cure the cancer and additionally achieve fer-
tility preservation poses several important considerations
both for the patient and the interdisciplinary oncologic
team. Due to the trend of delaying childbearing in
Western societies the interest in fertility preservation
might be rising in female cancer patients. For patients with
cervical cancer who have to undergo chemoradiation,
preservation of ovarian function and preservation of the
functionality of endometrial and myometrial structures
are of importance but remain a challenge in clinical
practice. Overcoming these problems would offer se-
lected patients the chance for both, cancer control and
preservation of fertility, including nidation of the ovule
in their own uterus e.g. carrying a child to term. Recent* Correspondence: pirus.ghadjar@charite.de
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cervical cancer treatment are critically discussed.Review
The preservation of ovarian function, cryo-conservation
and ovarian transposition
A successful pregnancy is dependent upon a functional
hypothalamic-pituitary-ovarian axis and the ability of the
uterus to receive nidation and to accommodate normal
growth of the fetus to term [2]. The nonrenewable pool of
ovarian primordial follicles declines through atresia with
age, from around 2 million at birth to 500.000 at menar-
che. Further decrease of the number of primordial follicles
is associated with an increased difficulty of spontaneous
conception during lifetime [3,4]. This natural decrease can
be aggravated by chemotherapy as well as radiation ther-
apy causing direct DNA damage to follicles. Ovarian tissue
is very sensitive to radiation [5]. It was estimated that ≤
2 Gy will destroy half of immature oocytes [4,6] and 4 Gy
produces infertility in a third of young women and in
almost all women over 40 years of age [7]. Childhood Can-
cer Survivor Study (CCSS) demonstrated that the occur-
rence of acute ovarian failure was not only associated with
older age at diagnosis but also with the conduction of ab-
dominal or pelvic radiation therapy, especially those who
received at least 10 Gy to the ovaries [8].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Transposition of the ovaries with ovarian vessels
within the paracolic gutter as high and lateral as possible.
Figure 2 Fixation of the ovaries with mobilized omentum and
identification mark for planning CT using titanium clips (orange).
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emotional and quality of life issue for pre-menopausal
women affected by cervical cancer [9]. However, methods of
ovarian preservation are often underused (only in 31 out of
108 patients) as demonstrated by Han et al. in a retrospect-
ive, single center study [10]. Ovarian function can be pre-
served either by cryo-conservation and re-transplantation of
ovarian tissue after oncologic treatment or by ovarian trans-
position (OT).
In current practice a proportion of young cervical cancer
patients undergo cryo-conservation of unfertilized oocytes
after appropriate ovarian stimulation [11]. Another estab-
lished option which however requires a partner is in vitro
fertilization (IVF) and cryo-preservation of embryos, which
is not regulated by legislation in several countries [9]. Alter-
natively ovarian tissue might be cryo-preserved and later be
re-implanted, preferably by an orthotopic approach, a pro-
cedure which requires no partner and no hormonal stimula-
tion [12]. Whether ovarian suppression through treatment
with gonodotropin-releasing hormone (GnRH) agonists or
antagonists during chemotherapy might help to maintain
fertility is controversially discussed [13]. First live birth after
cryo-preservation of ovarian tissue followed by transplant-
ation was described in 2004 in a woman with Hodgkin’s
lymphoma [12]. To the best of our knowledge until today
the birth of 18 healthy babies has been reported after trans-
plantation of frozen-thawed human ovarian tissue [14]. This
promising fertility preservation strategy has also been
described in a couple of young women affected by early cer-
vical cancer [15,16].
In order to reduce the dose applied to the ovaries OT is a
surgical procedure to move the ovaries and fallopian tube
outside the radiation volume by suturing them within the
paracolic gutter as high and lateral as possible (Figures 1
and 2) [17]. Hwang et al. demonstrated that fixation more
than 1.5 cm above iliac crest was the most important factor
for intact ovarian function [18]. OT can be done during
open radical hysterectomy, by laparoscopic approach or
more recently used robotic-assisted technique [19,20].
Therefore, maintaining of hormonal function can be
achieved in 70%-93% of women younger than 40 years
[21-26].
Successful deliveries after IVF stimulated oocyte re-
trieval from transposed ovary and transfer to surrogate
mothers have been described in patient treated for cervical
cancer [27-29]. However, metastases in transposed ovaries
also may occur occasionally [30-32]. Data for prevalence
of ovarian metastases in patients with cervical cancer in
the literature vary between 0% and 15%. Known risk
factors for ovarian spread are tumor size, histologic type
(squamous versus adenocarcinoma), grading, lymphovas-
cular space involvement and haemovascular involvement,
all of those having been discussed controversially
[24,33-36], however bilateral-oophorectomy is not part ofthe standard surgical management of cervical cancer. There-
fore, benefit of keeping hormonal function must be balanced
against (low) risk of ovarian metastases. We believe that OT
should be offered to all patients with cervical cancer younger
than 40 years without morphologic abnormalities in the
ovaries, stages I-IIB of disease with indication for primary or
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ian cancer after informed consent.
Chemotherapy related ovarian failure
Another reason of ovarian failure might be the application
of chemotherapy in combination with radiation therapy.
Most of the available literature on use of chemotherapy
and consecutive infertility is limited because of reporting
amenorrhea as a surrogate measure of infertility. Gener-
ally, a decrease of the total number of primordial follicles
could be detected after application of chemotherapeutic
drugs and it appears that alkylating agents have the high-
est risk of permanent amenorrhea, while the risk after
cisplatin-containing chemotherapy which is the drug of
choice in the treatment of cervical cancer, is considered to
be of intermediate risk for infertility [2,13]. Furthermore it
has been described that multi-agent chemotherapy with-
out radiation therapy was not associated with the occur-
rence and outcome of pregnancies [37].
Modern ovarian and uterine sparing techniques in
radiation oncology
Current pre-chemoradiation fertility preserving strategies
such as cryo-conservation of oocytes or ovarian tissue and
limitation of the dose applied to the ovaries [3], ultimately
were depending on the use a surrogate mother, as uterine
dysfunction after pelvic radiation therapy was assumed to
preclude to carry a pregnancy to term.
However, due to the availability of newer radiation therapy
techniques including intensity modulated radiation therapy
(IMRT) as well as CTand MRT based application of cervical
HDR-Brachytherapy or even HDR-Brachytherapy emulating
strategies e.g. using robotic radiosurgery, along with im-
proved fertility preservation methods by reproductive medi-
cine experts, today, the question arises whether fertility can
be preserved in young patients with cervical cancer includ-
ing the ability to carry a pregnancy to term. This would have
also forensic implications as third-party reproduction using
a gestational carrier is illegal in several European countries.
The radiosensitivity of the uterus appears to decrease with
advanced age as mentioned above but less data is available
from the literature regarding acute and late radiation dose
effects on the adult uterus. Milgrom et al. [38] recently de-
scribed the acute uterine effects after pelvic radiation ther-
apy with a median dose of 50.2 Gy (D95 of the uterus was
30 Gy) in 10 female (7 of which were pre-menopausal) rectal
cancer patients who underwent dynamic contrast-enhanced
MRI before and 4-7 weeks after radiation therapy. It was
found that the median cervical length was reduced after ra-
diation therapy. Interestingly 3 of the analyzed patients who
were initially pre-menopausal underwent ovarian transpos-
ition and maintained ovarian function after radiation therapy
and three other patients were post-menopausal before radi-
ation therapy. Thus in these 6 patients radiation inducedovarian failure would not account for the changes in uterine
anatomy. Moreover, in pre-menopausal patients the volume
transfer constant (Ktrans) and the extracellular extravascular
volume fraction (Ve) were significantly decreased after radi-
ation therapy, suggesting reduced perfusion of the pre-
menopausal myometrium after radiation therapy [38].
These functional changes of the uterus could both lead
to an impaired implantation of an embryo as well as
pregnancy-related complications [3]. The degree of damage
has been shown to be dependent on the total radiation dose
and it was shown that the pre-pubertal uterus is more vul-
nerable than the adult uterus to the effect of pelvic radi-
ation therapy, with doses of 14-30 Gy causing uterine
dysfunction [3,39,40]. It has been reported after total body
irradiation using 8.5-11.7 Gy total dose [41] or 14.4 Gy total
dose [2,40] in young female patients, that uterine growth
and blood flow were impaired. Likewise, after whole-
abdominal radiation therapy using 20-30 Gy during child-
hood the uterine length was shorter and endometrial
thickness was not increased after hormone replacement
suggesting irreversible damage to the uterus [39]. Others
have described in a cohort of 340 female cancer survivors
that after abdomino-pelvic radiation therapy the likelihood
to have low-birth-weight infants, premature low-birth-
weight infants and the perinatal infant mortality was in-
creased as compared to patients without radiation therapy.
These associations were dose dependent and the likeli-
hood to have low-birth-weight infants and perinatal infant
mortality were higher in patients receiving >25 Gy as com-
pared to total doses below 25 Gy [42]. Green et al. evalu-
ated the risk of fetal loss among 1915 female cancer
survivors of the CCSS. There was a trend for increased
miscarriages among women whose ovaries were near or
within the radiation volumes compared to patients with-
out radiation therapy. There was also a higher likelihood
of low-birth-weight infants found in patients who were
treated with pelvic radiation therapy [37]. Signorello et al.
[43] analyzed the risk of preterm birth among 1264 female
cancer survivors of the CCSS and found an increasing risk
of preterm birth with increasing cumulative dose to the
uterus. In contrast to the children of survivors who did
not receive any radiation therapy (among whom 19.6%
were born preterm), preterm birth was reported for 26.1%
of the children of survivors who received uterine doses in
the range of 0.5-2.5 Gy (odds ratio (OR) = 1.8, 95% confi-
dence interval (CI) = 1.1 to 3.0; P = .03), for 39.6% of the
children of survivors who received uterine doses in the
range of 2.5-5 Gy (OR = 2.3, 95% CI = 1.0 to 5.1; P = .04),
and for 50.0% of the children of survivors who received
uterine doses higher than 5 Gy (OR = 3.5, 95% CI = 1.5 to
8.0; P = .003). After stratification according to whether the
treatment occurred pre- or post-menarche it was found
that the association between uterine dose and preterm
birth appeared to be stronger for survivors exposed before
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P= .003) than those exposed after menarche (for >2.5 Gy,
OR= 1.9, 95% CI = 0.7 to 4.9; P= .21) suggesting that the
uterus is less sensitive to radiation dose with higher age.
Additionally, increasing dose to the uterus was found to be
related to the risk of low-birth weight (no radiation therapy
7.6%; uterine dose 2.5-5 Gy 25.5%; uterine dose >5 Gy
36.2% low-birth weight infants, respectively).
Sophisticated external beam irradiation techniques
(IMRT, volumetric arc therapy and helical tomotherapy)
offering by means of “dose painting” and sharp dose gradi-
ents against normal tissue a considerable dose reduction
not only to the transposed ovaries but also to the uterus it-
self. Figure 3 illustrates the isodoses in a patient undergo-
ing concurrent chemoradiation with RapidArc® technique.
The 95% isodose (95% of 50.4 Gy = 47.8 Gy) covers the
target volume including the cervix and the pelvic lymph
nodes. A selective dose reduction can be achieved for the
inner myo- and endometrial structures to avoid myome-
trial shrinkage and endometrial atrophy after radiation
therapy. A clear dose correlation for endometrial function-
ality had not been established yet. According to glandular
function of other organs (e.g. parotid gland) we try to keep
the mean dose <20-25 Gy (Figure 3 A, B and C).
The current recommendations for target volume delin-
eation using IMRT in cervical cancer however recom-
mend to include the entire uterus into the clinical targetFigure 3 Isodoses of the prescribed dose (47.8 Gy) in the target
volume decreasing to the periphery and to the ovaries (in black
circles) to < 2 Gy between second (L2) and third (L3) lumbar
vertebrar. Selective dose reduction within the intact uterus from 40 Gy
(A) to 30 Gy (B) in the periphery to 20 Gy (C) in the inner layer of the
myometrium and endometrium.volume (CTV) because uterus and cervix are embryologic-
ally one unit with interconnected lymphatics and no clear
separating fascial plane. It was not clear how often and
where intrauterine recurrences occur after chemoradiation
for cervical cancer [44]. However, the question whether
the uterus has to be included completely or partially into
the CTV was discussed controversially amongst involved
experts. 42 percent of survey respondents felt that it was
not always necessary to include the entire uterus in the
CTV and it was stated that excluding a portion of the cor-
pus would be an option for selected cases when sufficient
data are available regarding the incidence and exact loca-
tion of uterine recurrence after conservative surgical pro-
cedures [44]. On the other hand, the assumption that all
structures of one embryologic compartment should be in-
cluded into the target remains controversial since radical
trachelectomy has been demonstrated excellent results
while preserving the uterus and oophorectomy is not con-
sidered a standard procedure in this setting [45]. However,
the results of trachelectomy might not be transferred to
patients undergoing chemoradiation as the latter usually
have more advanced disease.
When IMRT should be used to spare healthy uterine tis-
sue, an appropriate management of uterine motion is cru-
cial, as interfractional uterine movement has been well
described by others [46]. Besides bladder and rectum filling
recommendations we recommend daily soft-tissue imaging
with correction for interfractional motion or adaptive re-
planning if deemed necessary.
With the use of MRI guided brachytherapy, the extent
of the macroscopic tumor can be exactly determined
and the uninvolved corpus uteri should not be part of
the target volume [47].
Furthermore we have shown that HDR-Brachytherapy
(which is regarded as the standard technique for dose es-
calation to the cervix) can be emulated by Cyberknife ro-
botic radiosurgery with an excellent target coverage and
steep dose gradients toward normal surrounding tissues
[48,49]. This approach might further contribute to spare
the dose to the uterus. As a cautionary note, it is not de-
finitively known yet to what extent the function of the cer-
vix itself might be compromised, after the package of
external beam radiation therapy, HDR-Brachytherapy (or
Brachytherapy emulating stereotactic external beam radi-
ation therapy) with a nominal total dose of around 90 Gy,
potentially leading to pregnancy related complications.
However, as uterine sparring radiation therapy of cer-
vical cancer is a non-established approach we must be
fully aware about the potential disadvantages which might
be associated with its use (compromised cancer control
maybe even without successful fertility preservation) and
treat, if at all, patients within prospective protocols after
careful selection. In our center, we offer uterus sparing
treatment on request after informed consent to selected
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clude young women who request fertility preservation and
underwent OT with Stage IA2-IB1 disease in the presence
of one or more risk factors demanding chemoradiation
such as pN1, pM1 (LYM), V1, L1 or G3.
To emphasize it again, patients must be aware about a
potentially higher risk of recurrence and the risk for preg-
nancy related complications before they chose this kind of
approach.
Conclusions
High-precision modern radiation therapy techniques may
allow uterine sparing chemoradiation e.g. to reduce the
planned dose to the non-affected uterus to below 20-25 Gy.
Whether this may preserve fertility, including the ability to
carry a pregnancy to term after cancer treatment without
compromised cancer control is fully unclear and great cau-
tion must remain. It is therefore mandatory, if considered to
use this strategy for selected patients, to treat patients within
prospective trials.
Search strategy and selection criteria
References for this Review were identified through searches
of PubMed with the search terms “cervical cancer”, “radi-
ation therapy”, “fertility”, and “preservation” from 1990 until
February, 2014. Articles were also identified through
searches of references of these articles. Only papers pub-
lished in English were reviewed. The final reference list was
generated on the basis of originality and relevance to the
broad scope of this review article.
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